56 completed, 15 recruiting, 10 active not recruiting, 4 not yet recruiting. 35 Phase 3, 19 Phase 1, 18 Phase 2, 11 Phase 4, 1 Not applicable.
Follow risankizumab: new trials by email Literature Review of risankizumab trials Research Report on risankizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Risankizumab for Refractory Perianal Fistulizing Crohn's Disease Risankizumab - Crohn Disease, Perianal Fistula | Phase 4 | Not yet recruiting | Yuki Horio | 25 | 2026-10-01 | 2026-10-19 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis Risankizumab, Trosunilimab, ABBV-701 - Crohn's Disease, Ulcerative Colitis | Phase 2 | Recruiting | AbbVie | 2000 | 2026-07-31 | 2026-10-20 |
| A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants Risankizumab - Healthy Volunteer | Phase 1 | Recruiting | AbbVie | 60 | 2026-06-04 | 2026-07-01 |
| Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease Guselkumab (GUS), Risankizumab (RISA) - Psoriasis, Psoriasis Arthritis | Not yet recruiting | Caja Costarricense de Seguro Social | 50 | 2026-05-01 | 2026-03-09 | |
| A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Guselkumab, Risankizumab - Crohn Disease | Phase 3 | Recruiting | Janssen Research & Development, LLC | 530 | 2026-04-21 | 2026-09-25 |
| Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population Non-Interventional Study - Ulcerative Colitis | Active not recruiting | Pfizer | 4000 | 2026-04-01 | 2026-10-15 | |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants SKYRIZI, CKD-704 - Psoriasis | Phase 1 | Recruiting | Chong Kun Dang Pharmaceutical | 213 | 2025-11-26 | 2025-12-19 |
| Risankizumab for Fibrostenotic Crohn's Disease Treatment Ustekinumab, Risankizumab - Crohn Disease, Crohn Disease and Ulcerative Colitis | Phase 3 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 260 | 2025-10-20 | 2025-09-16 |
| A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis Risankizumab - Ulcerative Colitis | Phase 3 | Recruiting | AbbVie | 120 | 2025-07-28 | 2026-10-22 |
| A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab Risankizumab, Vedolizumab - Ulcerative Colitis | Phase 3 | Active not recruiting | AbbVie | 573 | 2025-06-17 | 2026-08-04 |
| A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants Risankizumab - Healthy Volunteers | Phase 1 | Completed | AbbVie | 260 | 2025-06-12 | 2026-01-27 |
| A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants Risankizumab - Healthy Volunteers | Phase 1 | Completed | AbbVie | 59 | 2025-05-08 | 2025-12-26 |
| A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants Risankizumab - Healthy Volunteer | Phase 1 | Completed | AbbVie | 263 | 2025-04-21 | 2025-11-17 |
| Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis Lutikizumab, Risankizumab - Psoriatic Arthritis | Phase 2 | Recruiting | AbbVie | 120 | 2025-04-11 | 2025-12-18 |
| Risankizumab in Children With Crohn's Disease (RisaKids) Risankizumab - Crohn Disease | Not applicable | Recruiting | Shaare Zedek Medical Center | 90 | 2024-10-31 | 2024-12-03 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis Bimekizumab, Risankizumab, Placebo - Psoriatic Arthritis | Phase 3 | Completed | UCB Biopharma SRL | 553 | 2024-10-21 | 2026-09-02 |
| Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response Sonelokimab, Placebo, Risankizumab - Arthritis, Psoriatic | Phase 3 | Active not recruiting | MoonLake Immunotherapeutics AG | 600 | 2024-10-15 | 2026-10-09 |
| Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease Fluconazole, Placebo, IL-23 Therapy - Crohn's Disease, Inflammatory Bowel Diseases | Phase 3 | Recruiting | Weill Medical College of Cornell University | 120 | 2024-10-04 | 2026-08-20 |
Showing 20 of 89. Sign in to see all of them.
Psoriasis (32) · Crohn Disease (21) · Arthritis, Psoriatic (11) · Colitis, Ulcerative (10) · Skin Diseases (3) · Skin Diseases, Papulosquamous (3) · Arthritis, Juvenile (2) · Dermatitis, Atopic (2) · Inflammatory Bowel Diseases (2) · Spondylitis, Ankylosing (2) · Arthritis (1) · Arthritis, Rheumatoid (1) · Asthma (1) · Breast Feeding (1) · COVID-19 (1)
AbbVie (67) · Janssen Research & Development, LLC (2) · Alimentiv Inc. (1) · Boehringer Ingelheim (1) · Caja Costarricense de Seguro Social (1) · Chong Kun Dang Pharmaceutical (1) · First Affiliated Hospital of Wenzhou Medical University (1) · Istituto Clinico Humanitas (1) · Jaehwan Kim (1) · MoonLake Immunotherapeutics AG (1) · NYU Langone Health (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Oregon Medical Research Center (1) · Pfizer (1) · Radboud University Medical Center (1)
United States (59) · Canada (32) · Germany (31) · Poland (26) · United Kingdom (26) · Spain (25) · Belgium (18) · France (18) · Israel (18) · Italy (18) · Netherlands (18) · Japan (17) · Czechia (16) · South Korea (16) · Taiwan (14)
Benjamin D Ehst, MD, PhD (1) · Elke de Jong, MD, PhD (1) · Jaehwan Kim, MD, PhD (1) · Jonathan Samuels, MD (1) · Kevin Cooper, MD (1) · Lawrence Mcnamee (1) · Marc Ferrante, Professor (1) · Randy Longman, MD, PhD (1) · Raymond Cho, MD, PhD (1)
PMID 31054118, PMID 31667790, PMID 36178584, PMID 34921669, PMID 38863178, PMID 37368103, PMID 39054592, PMID 39131711, PMID 39485390, PMID 33052382, PMID 35644154, PMID 35839335, PMID 35931879, PMID 38739215, PMID 39037800, PMID 39073712, PMID 39120849, PMID 39802486, PMID 39804294, PMID 39909280, PMID 40168091, PMID 40953785, PMID 41028616, PMID 41318485, PMID 28411872, PMID 28423301, PMID 29945918, PMID 30056030, PMID 30097359, PMID 30574672, PMID 31237727, PMID 32267471, PMID 33512666, PMID 33947295, PMID 34077509, PMID 34157132, PMID 34473343, PMID 34656148, PMID 34706172, PMID 34815219, PMID 34911706, PMID 35050485, PMID 35644155, PMID 35701011, PMID 35801915, PMID 35917057, PMID 36282530, PMID 36282537, PMID 36588137, PMID 36892753
2023 (7), 2016 (6), 2015 (5), 2014 (4), 2019 (4), 2017 (2), 2025 (1), K23AR080043 (1)